Tweets
Can we prevent psoriatic arthritis? Highlights from #EULAR2024 that help us understand this topic better @RheumNow https://t.co/E8Wy8FH4oU
Dr. Antoni Chan @synovialjoints ( View Tweet )
2 years ago
#Vaccinations against #herpes #zoster in #MTX +#Upadacitinib Pts
▶️ #Shingrix works
👍Pts followed to 60 months
#EULAR2024
@eular_org @RheumNow
#OP0020 https://t.co/8ORC3Nd2FK
Janet Pope @Janetbirdope ( View Tweet )
2 years ago
OP0018 @RheumNow #EULAR2024
🔎 Study looked at early RA patient trajectories through time-independent disease state
📊 Authors demonstrated 4⃣ trajectories in early RA
🦴 Inflammation in joints, blood & poor response are main discriminatory factors https://t.co/IeDIU3jg9B
Mrinalini Dey @DrMiniDey ( View Tweet )
2 years ago
➡️ OP0064 @RheumNow #EULAR2024
➡️ Non-articular pain (NAP) at early RA diagnosis & evolution over the first yr of RA treatment
➡️ NAP, esp regional NAP, common in early RA during 1st yr
➡️ NAP in axial, both upper quadrants and both lower quadrants common https://t.co/FOGcS05Z25
Mrinalini Dey @DrMiniDey ( View Tweet )
2 years ago
OP0086 #EULAR2024 @RheumNow #EULARBest
Pain & remission/low disease activity at 3m in pts with #RA in RA-BE-REAL
Pts taking #baricitinib more likely to achieve pain control vs TNFi/other mode of action
1/2 pts achieving remission/LDA & had bari achieved ≥70% pain relief.
Mrinalini Dey @DrMiniDey ( View Tweet )
2 years ago
TOLERA trial in RA
RTX/ABA sequence versus RTX alone
10pts each group
Primary outcome was ambitious: ACPA seroconversion
No difference between ttmts (and also no seroconversion)
No diff in disease activity
No diff in ACPA change wt wk52
@RheumNow OP0069 #EULAR2024 https://t.co/0EM7XRzfNo
Aurelie Najm @AurelieRheumo ( View Tweet )
2 years ago
200 millions pts PSO
1st line, Reduction risk PsA: IL 12-23 37% & IL-23 39% vs. TNFi
2nd line ttmt, IL12-23i 32% & IL-23i 31%
IL-23i 47% lower proba PsA than IL-17i 3 & 5 yrs
Can't exclude some channeling bias, but that's a big signal!
@RheumNow OP0010 #EULAR2024 #EULARBest
Aurelie Najm @AurelieRheumo ( View Tweet )
2 years ago
AMPLIFIED RCT, 300+ pts
ABA NOT (!) superior to ADA
in dual seropositive SE+ MTX IR RA pts
ACR50 rate high in both gps ABA 59% vs ADA 64%
No new safety signal
Defeating the encouraging data from smaller trials
Abstr#OP0007 #EULAR2024 @RheumNow https://t.co/PvRUnpthHl
Aurelie Najm @AurelieRheumo ( View Tweet )
2 years ago
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty.
Dr. John Cush @RheumNow ( View Tweet )
2 years ago
What is the origin of pain in difficult to manage axSpA?
1- Inflammation
2- Degenerative
3- Central Nervous System
#EULAR2024
NZ https://t.co/KzATnYN4HG
Annals of the Rheumatic Diseases @ARD_BMJ ( View Tweet )
2 years ago
Ph III RCT SHR0302 JAK1 selective inhibitor in RA
500+ pts
ACR20 wk 24 SHR0302 8mg & 4mg PBO 75% 70% 40%
ACR70 wk 24 SHR0302 8mg & 4mg PBO 31% 22% 7%
Safety similar other JAKi
Abstr#OP0037 #EULAR24 @RheumNow https://t.co/6ZuvT6czo8
Aurelie Najm @AurelieRheumo ( View Tweet )
2 years ago
Digital biomarkers are also going to be useful int he future - from devices such as phone / watches.
Bella Mehta @bella_mehta ( View Tweet )
2 years ago
